UNSPSC 51434950: Hydrochlorothiazide/timolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434950 Hydrochlorothiazide/timolol is a Commodity code under which state and local governments procure specific branded and generic medications for emergency response, hospital, and public health programs. Recent solicitations show that state and local buyers are acquiring advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through both individual agency procurements and cooperative purchasing vehicles. The City of Tampa's Fire Rescue department, for example, solicited advanced life support medications including epinephrine, adenosine, diltiazem, and labetalol—drugs used in cardiac arrest and emergency response protocols—while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a broader RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon. Issuing bodies include city purchasing departments managing emergency medical supplies, state health and human services agencies exploring direct-to-manufacturer prescription models, and multistate cooperative purchasing alliances. The code does not map cleanly to recent activity; the Tampa and MMCAP opportunities show procurement of emergency and general-use medications, but hydrochlorothiazide/timolol is a specific antihypertensive combination therapy not explicitly named in the recent solicitations reviewed.

Geographic activity centers on Florida, Texas, and Minnesota based on recent opportunities. The City of Tampa issued an IFB (Bid No. 26-P-00188) for advanced life support medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, with a one-year term and two optional one-year renewals plus three discretionary 30-day extensions; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation not to exceed $10,000. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in alternative pharmaceutical supply models outside traditional pharmacy benefit managers and group purchasing organizations. MMCAP's RFP (due March 26, 2026) established contracts effective July 1, 2026 for generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with pricing weighted 75 percent on competitiveness and vendors required to maintain $2 million network security and privacy liability coverage and $2 million professional liability coverage.